Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials
- 13 October 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 396 (10261), 1491-1503
- https://doi.org/10.1016/s0140-6736(20)32014-6
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing storyBiotechnology Letters, 2015
- Virus-specific T cells as correlate of (cross-)protective immunity against influenzaVaccine, 2015
- Biochemical composition of haemagglutinin‐based influenza virus‐like particle vaccine produced by transient expression in tobacco plantsPlant Biotechnology Journal, 2014
- Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccinesVaccine, 2014
- Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trialVaccine, 2014
- Egg‐ or cell culture‐derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccinesBiotechnology Journal, 2013
- Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humansNature Medicine, 2012
- WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: Supporting developing country production capacity through technology transferVaccine, 2011
- Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy AdultsClinical Infectious Diseases, 2010
- Influenza virus‐like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in micePlant Biotechnology Journal, 2008